{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:07:31Z","timestamp":1789708051066,"version":"4.0.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Japan Clinical Cancer Research Organization"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10549-023-07030-x","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T10:01:34Z","timestamp":1690020094000},"page":"409-415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03)"],"prefix":"10.1007","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6639-0468","authenticated-orcid":false,"given":"Kokoro","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Yoshinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Toi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,22]]},"reference":[{"key":"7030_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.breast.2016.10.005","volume":"31","author":"M Sundquist","year":"2017","unstructured":"Sundquist M, Brudin L, Tejler G (2017) Improved survival in metastatic breast cancer 1985\u20132016. Breast 31:46\u201350. https:\/\/doi.org\/10.1016\/j.breast.2016.10.005","journal-title":"Breast"},{"key":"7030_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12282-019-01021-x","volume":"27","author":"H Iwata","year":"2020","unstructured":"Iwata H, Saji S, Ikeda M, Inokuchi M, Uematsu T, Toyama T, Horii R, Yamauchi C (2020) The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient. Breast Cancer 27:1\u20133. https:\/\/doi.org\/10.1007\/s12282-019-01021-x","journal-title":"Breast Cancer"},{"key":"7030_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","volume":"4","author":"MA Jordan","year":"2005","unstructured":"Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086\u20131095. https:\/\/doi.org\/10.1158\/1535-7163.MCT-04-0345","journal-title":"Mol Cancer Ther"},{"key":"7030_CR4","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","volume":"105","author":"Y Funahashi","year":"2014","unstructured":"Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, Tohyama O, Uehara T, Kimura T, Watanabe H, Asano M (2014) Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 105:1334\u20131342. https:\/\/doi.org\/10.1111\/cas.12488","journal-title":"Cancer Sci"},{"key":"7030_CR5","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Di\u00e9ras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C, EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician\u2019s Choice Versus E7389) investigators (2011) Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914\u2013923. https:\/\/doi.org\/10.1016\/S0140-6736(11)60070-6","journal-title":"Lancet"},{"key":"7030_CR6","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J (2015) Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33:594\u2013601. https:\/\/doi.org\/10.1200\/JCO.2013.52.4892","journal-title":"J Clin Oncol"},{"key":"7030_CR7","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1200\/JCO.2010.31.5374","volume":"29","author":"A Gennari","year":"2011","unstructured":"Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, Wilcken N, D\u2019Amico M, DeCensi A, Bruzzi P (2011) Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 29:2144\u20132149. https:\/\/doi.org\/10.1200\/JCO.2010.31.5374","journal-title":"J Clin Oncol"},{"key":"7030_CR8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s12282-018-0843-y","volume":"25","author":"S Ohtani","year":"2018","unstructured":"Ohtani S, Nakayama T, Yoshinami T, Watanabe KI, Hara F, Sagara Y, Kawaguchi H, Higaki K, Matsunami N, Hasegawa Y, Takahashi M, Mizutani M, Morimoto T, Sato M, Itoh M, Morita S, Masuda N (2018) Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY). Breast Cancer 25:438\u2013446. https:\/\/doi.org\/10.1007\/s12282-018-0843-y","journal-title":"Breast Cancer"},{"key":"7030_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10549-004-2468-4","volume":"90","author":"SY Rha","year":"2005","unstructured":"Rha SY, Moon YH, Jeung HC, Kim YT, Sohn JH, Yang WI, Suh CO, Kim GE, Roh JK, Chung HC (2005) Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 90:215\u2013221. https:\/\/doi.org\/10.1007\/s10549-004-2468-4","journal-title":"Breast Cancer Res Treat"},{"key":"7030_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/jjco\/hyi090","volume":"35","author":"M Toi","year":"2005","unstructured":"Toi M, Saeki T, Aogi K, Sano M, Hatake K, Asaga T, Tokuda Y, Mitsuyama S, Kimura M, Kobayashi T, Tamura M, Tabei T, Shin E, Nishimura R, Ohno S, Takashima S (2005) Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. Jpn J Clin Oncol 35:310\u2013315. https:\/\/doi.org\/10.1093\/jjco\/hyi090","journal-title":"Jpn J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07030-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-07030-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07030-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T12:16:30Z","timestamp":1693138590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-07030-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,22]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["7030"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-07030-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,22]]},"assertion":[{"value":"11 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KK has received honoraria from Pfizer, Eisai, Eli lily, Chugai, Taiho, Novartis, AstraZeneca. NM has received honoraria from Chugai, Pfizer, AstraZeneca and Eli Lilly. NM\u2019s institution received grants from Chugai, Eli Lilly, AstraZeneca, Pfizer, Daiichi Sankyo, MSD, Eisai, Novartis, Sanofi, Kyowa Kirin, Nippon Kayaku and Ono; and has been involved in the Japan Breast Cancer Research Group (JBCRG) and Japanese Breast Cancer Society (JBCS) as a board of directors. TM has received honoraria from Chugai, Pfizer, Eisai, MSD, Ono, Daiichi Sankyo, Eli Lilly and AstraZeneca. TY has received Consulting fee from Eisai; and honoraria from Chugai, Eli Lilly, Kyowa Kirin, Daiichi Sankyo, MSD, Pfizer, Novartis, Eisai and Astra Zeneca. HK has received honoraria from Pfizer, Chugai, Astra Zeneca, Eisai, Kyowa Kirin, Novartis, Maruho, Eli Lilly, Taiho, Daiichi Sankyo and Nippon Kayaku. SO has received honoraria from Lilly, Chugai, Pfizer and Daiichi Sankyo. TS has received honoraria from Taiho, Daiichi Sankyo, Chugai, Pfizer, and Eli Lilly. MT has received research grant from Chugai, Takeda, Pfizer, Taiho, JBCRG, Kyoto Breast Cancer Research Network (KBCRN), Eisai, Eli Lilly and companies, Daiichi Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult Honsha, Nippon Kayaku, AFI technology, Luxonus, Shionogi, GL Science, Sanwa Shurui; honoraria from Chugai, Takeda, Pfizer, Kyowa Kirin, Taiho, Eisai, Daiichi Sankyo, AstraZeneca, Eli Lilly and companies, MSD, Exact Science, Novartis, Shimadzu, Yakult, Nippon Kayaku, Devicore Medical Japan and Sysmex; advisory board member of Daiichi Sankyo, Eli Lilly and companies, BMS, Athenex Oncology, Bertis, Terumo and Kansai Medical Net; has been involved in JBCRG as the board of directors, KBCRN as the board of directors, OOTR as the board of directors and JBCS as the Chairman of the board of directors; and associate editor of British Journal of Cancer, Scientific Reports, Breast Cancer Research and Treatment, Cancer Science, Frontiers in Women\u2019s Cancer, Asian Journal of Surgery and Asian Journal of Breast Surgery. YI has received research funding from Chugai, MSD, Eli Lilly, Daiichi Sankyo and AstraZeneca. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in compliance with the Japanese guidelines and the Declaration of Helsinki. The study was approved by the institutional review boards of all participating institutions. Written informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}